Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986278 in Progressive Pulmonary Fibrosis
NCT06025578Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 35
01
Overview
Phase 3, randomised, double-blind trial of admilparant in pulmonary fibrosis (PF) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants that experience spontaneous syncopal events at 4 weeks and Absolute change from baseline in forced vital capacity (FVC) at Week 52. Started Oct 2023; status: active, not recruiting.
02
Drugs
admilparant
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT06025578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06025578.